GSK's injectable HIV drug shows promise over daily pills
Send a link to a friend
[February 21, 2024]
(Reuters) - British drugmaker GSK said on Wednesday its
long-acting injectable HIV therapy showed promise in keeping the viral
load suppressed compared to daily oral treatment, especially in
individuals facing challenges with pill intake.
The interim analysis of a late-stage trial on the therapy known as
Cabenuva demonstrated superior efficacy in maintaining viral load
suppression compared to daily oral therapy in individuals with a history
of adherence challenges to oral antiretroviral treatment, which is used
to suppress and mitigate the progression of the disease.
The lack of consistent adherence is a common reason why some people
living with HIV struggle to keep the virus in check, GSK said.
The drug falls under GSK's ViiV Healthcare business, in which Pfizer and
Shionogi hold small stakes.
Strong sales of medicines for HIV, the virus that causes AIDS, were one
of the drivers behind the company's performance last year, generating
6.44 billion pounds ($8.13 billion) in annual sales. It is a key element
of CEO Emma Walmsley's push to enhance investor confidence in the
strength of GSK's drug development pipeline.
[to top of second column]
|
![](../images/022124PIX/health19.jpg)
GSK (GlaxoSmithKline) logo is seen in this illustration, August 10,
2022. REUTERS/Dado Ruvic/Illustration/File Photo
![](http://archives.lincolndailynews.com/2024/Feb/21/images/ads/current/zionpulaski_lda_EDUCATION_2024.png) Cabenuva sales more than doubled to
708 million pounds last year.
($1 = 0.7921 pounds)
(Reporting by Eva Mathews in Bengaluru; Editing by Dhanya Ann
Thoppil)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2024/Feb/21/images/ads/current/ldn_smallsda_BUSINESSMAG_2023.png) |